Wealth Enhancement Trust Services’s Entrada Therapeutics TRDA Stock Holding History

Wealth Enhancement Trust Services’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$316	Buy	+43	New	+$412	﹤0.01%	1300

Other funds holding TRDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $508M AUM 163.77% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wealth Enhancement Trust Services's TRDA Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Entrada Therapeutics (TRDA) in Q2 2026: 43 shares worth $316. The stake represents ﹤0.01% of the portfolio and ranks #1300 among its holdings.

58 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

Wealth Enhancement Trust Services held 43 shares of Entrada Therapeutics worth $316 as of Q2 2026.
Entrada Therapeutics was a new Wealth Enhancement Trust Services position in Q2 2026.
Entrada Therapeutics made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #1300 holding.
58 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.